Log In
BCIQ
Print this Print this
 

anti-MUC1 AR20.5, BrevaRex MAb-AR20.5 Anti-MUC1 Mab

  Manage Alerts
Collapse Summary General Information
Company Quest PharmaTech Inc.
Description mAb against MUC1
Molecular Target Mucin 1 (MUC1) (CD227)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationPancreatic cancer
Indication DetailsTreat pancreatic cancer
Regulatory Designation
PartnerOncoVent Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/18/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today